Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II , at 59 %, with the overall attrition rate for breast cancer standing at 85 %.
- How do failure rates vary by stage of development , molecule type , and molecular target ?
- How do other factors , such as average trial duration and trial size , influence the costs and risks associated with product development ?
The breast cancer Southeast Asian market will be valued at $ 2.7 billion in 2022 , growing from $ 942.3m in 2015 at a CAGR of 16.2 %.
- Despite an array of treatments being available for breast cancer , there is still an unmet need in the Southeast Asian markets related to low uptake of targeted therapies . Will this scenario change during the forecast period ?
Market forecasts indicate that South Korea will continue to be the largest market in Southeast Asia , due to the emergence of novel therapies and the continued uptake of branded therapies .
- How will the annual cost of therapy and market size vary between the eight Southeast Asian markets ?
Download sample Copy of This Report at : http :// www . radiantinsights . com / research / breast-cancer-therapeutics-in-southeastasia-markets-to-2022 / request-sample
- What are the factors that contribute to the increase in ACoT and market size for each of the assessed countries ?
- How will branded therapies be affected by upcoming pipeline therapies in each of the assessed countries ?
- How will the potential launch of biosimilars influence each country ?
- Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs ?
Various drivers and barriers will influence the market over the forecast period . - What barriers limit the uptake of premium-priced therapeutics in the assessed countries ? - What factors are most likely to drive the market in these countries ?
Reasons to buy This report will allow you to -
Follow Us :